In this single-institution, matched cohort study with median follow-up of 11.4 years, patients diagnosed with and treated for breast cancer during pregnancy with chemotherapy had at least comparable,…
Sameem Abedin, MD, Medical College of Wisconsin, Milwaukee, WI, discusses a Phase I study investigating CLAG-M salvage chemotherapy and lintuzumab-Ac225, a radio-labeled antibody against CD33,…
Neoadjuvant chemotherapy’s effect on local disease management of breast cancer has a number of clinical implications, including tumor downsizing, potentially improved overall survival, and more.
While pancreatic cancer rates are rising in people under age 50, a new survey conducted by the OSUCCC – James shows most people continue to…
Walid Khaled, PhD, on Friday discussed work to draw a map of how the breast changes during tumorigenesis and progression.
China’s NMPA has granted priority review to the NDA for savolitinib plus osimertinib in pretreated EGFR-mutated advanced NSCLC with MET amplification.
A biologics license application for TLX250-CDx has been submitted to the FDA, as supported by the phase 3 ZIRCON trial showing high accuracy for ccRCC…
The European Commission has approved a type II variation extended indication for lazertinib plus amivantamab in frontline EGFR-mutated NSCLC.
Fred Hutch Cancer Center’s Lonnie A. Nelson, PhD; Jason Mendoza, MD, MPH; and Myra Parker, JD, MPH, PhD, were awarded a U19 cooperative agreement from…
